Why the study?
Does systemic lupus erythematosus increase the risk of premature subclinical coronary atherosclerosis in premenopausal women?
Case-Control (n=120)
Does systemic lupus erythematosus increase the risk of premature subclinical coronary atherosclerosis in premenopausal women?
Premenopausal women with SLE have a significantly higher burden of subclinical coronary atherosclerosis compared to healthy controls, which correlates with disease activity and inflammatory markers.
Supports subclinical CAD evaluation in premenopausal SLE; leaves open prospective confirmation of inflammatory risk drivers.
To elucidate early coronary atherosclerotic changes in premenopausal systemic lupus erythematosus (SLE) female patients without clinical cardiovascular manifestation using a 64-slice Multi-detector computed tomography (MDCT) scan to detect coronary calcification and measure coronary calcium score (CCS), and to find out its correlation to some traditional and non-traditional risk factors. Sixty consecutive premenopausal SLE female patients, and sixty age and sex matched healthy subjects without known systemic, immunological, or cardiovascular disease (served as a control group) underwent clinical examination, serological analysis, and 64-slice MDCT-based coronary calcium scoring. All the clinical, serological, and MDCT parameters of the patients were correlated. Coronary calcification (CC) was seen in 21 patients (35%), the number of atherosclerotic calcified plaques ranged from 0 to 19. Calcium scores ranged from 0 to 843. In contrast to control subjects, SLE patients had significantly higher erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), total cholesterol level, low-density lipoprotein (LDL), immunoglobulin G (IgG) and IgM anti-cardiolipin antibodies, serum intracellular adhesion molecule (sICAM) and E-selectin levels. SLE patients had highly significantly more atherosclerotic plaques (3 ± 0.66 compared to 0.1 ± 0.07, p < 0.001) and higher CCS (59.2 ± 20.3 compared to 2.6 ± 1.85, p < 0.001). Significant positive correlation was found between both number of atherosclerotic plaques and CCS and total cholesterol level, LDL, cumulative prednisone dose, SLE disease activity index (SLEDAI), ESR, CRP, sICAM-1, E-Selectin, and anti-cardiolipin antibodies (p < 0.05 in all). Pre-menopausal SLE female patients free from clinical atherosclerotic vascular disease have an increased number of atherosclerotic plaques and CCS, which correlate positively with SLEDAI disease activity score, serum CRP, anticardiolipin antibodies, sICAM-1, E-Selectin, LDL level, total cholesterol level, and cumulative prednisone dose. In addition, we conclude that MDCT is a non-invasive, sensitive, reproducible, and reliable tool for accurate measurement of coronary calcification.
No takes yet. Share an insight, caveat, or question.
Othman et al. (2013) conducted a case-control in Systemic lupus erythematosus (n=120). Systemic lupus erythematosus vs. Healthy subjects without known systemic, immunological, or cardiovascular disease was evaluated on Coronary calcium score (CCS) (p=< 0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: